News BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 10/04/2026 pm IST			5-day change	1st Jan Change
326.80 ^SEK	-0.24%		-0.18%	+5.15%

27/03	BioArctic proposes board expansion with new appointments	FW
27/03	Bioarctic AB Announces Declining of Re-Election by Pär Gellerfors as Board Member	CI

All News

27/03	BioArctic proposes board expansion with new appointments	FW
27/03	The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB	AQ
27/03	Bioarctic AB Announces Declining of Re-Election by Pär Gellerfors as Board Member	CI
23/03	Eisai Present New Data on Long-Term Real-World Treatment with Lecanemab	CI
23/03	BioArctic AB Partner Eisai Presents New Data on Lecanemab At 2026 AD/PDTM Congress	CI
23/03	BioArctic : New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress	PU
23/03	BioArctic : New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress	PU
20/03	Eisai Co Ltd And Biogen Inc Announce Real-World Long-Term Treatment Persistence With Leqembi	CI
20/03	Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United States	CI
20/03	UK to reconsider NHS rejection of Alzheimer's drugs from Eli Lilly and BioArctic (Update)	FW
20/03	UK to Reconsider Rejection of Eli Lilly's Alzheimer's Drug - BN	FW
16/03	Lannebo Sverige Plus rose 7.0 percent in February - increased bank holdings	FW
16/03	Lannebo Sverige climbed 7.4 percent in February ? increased positions in SEB, Nordea, and Swedbank	FW
12/03	Scandibio recruits 200 patients for Phase 3 Alzheimer's study	FW
11/03	BioArctic partner to present long-term lecanemab data at AD/PD conference	FW
11/03	Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress	AQ
27/02	Number of shares and votes in BioArctic AB (publ) as of February 27, 2026	AQ
24/02	BioArctic (Q4 review): High quality, high expectations	AQ
20/02	Nordea Raises Price Target for Bioarctic to 240 Kronor (236), Reiterates Sell	FW
19/02	Lannebo Health and New Technology Down 5.1 Percent in January — Bico and Raysearch Weigh on Performance	FW
19/02	Goldman Sachs Raises Price Target for Bioarctic to 367 Kronor (346), Reiterates Buy - BN	FW
18/02	Stockholm Stock Exchange Hits All-Time High on Wednesday, OMXS30 Index Up 1.2 Percent	FW
18/02	Stockholm Stock Exchange Continues Upward Trend at Lunchtime, OMXS30 Index Rises 0.7 Percent	FW
18/02	Bioarctic AB Proposes Dividend for the Financial Year 2025	CI
18/02	BioArctic AB, Q4 2025 Earnings Call, Feb 18, 2026